- Home
- BMEA vs IROQ Comparison
BMEA vs IROQ Comparison
Compare BMEA & IROQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- IROQ
- Stock Information
- Founded
- BMEA 2017
- IROQ 1883
- Country
- BMEA United States
- IROQ United States
- Employees
- BMEA N/A
- IROQ N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- IROQ Savings Institutions
- Sector
- BMEA Health Care
- IROQ Finance
- Exchange
- BMEA Nasdaq
- IROQ Nasdaq
- Market Cap
- BMEA 65.8M
- IROQ 79.4M
- IPO Year
- BMEA 2021
- IROQ 2011
- Fundamental
- Price
- BMEA $1.71
- IROQ $24.81
- Analyst Decision
- BMEA Strong Buy
- IROQ
- Analyst Count
- BMEA 10
- IROQ 0
- Target Price
- BMEA $21.00
- IROQ N/A
- AVG Volume (30 Days)
- BMEA 1.1M
- IROQ 1.3K
- Earning Date
- BMEA 08-04-2025
- IROQ 08-28-2025
- Dividend Yield
- BMEA N/A
- IROQ 1.60%
- EPS Growth
- BMEA N/A
- IROQ 69.23
- EPS
- BMEA N/A
- IROQ 1.05
- Revenue
- BMEA N/A
- IROQ $25,099,000.00
- Revenue This Year
- BMEA N/A
- IROQ N/A
- Revenue Next Year
- BMEA N/A
- IROQ N/A
- P/E Ratio
- BMEA N/A
- IROQ $23.87
- Revenue Growth
- BMEA N/A
- IROQ 12.02
- 52 Week Low
- BMEA $1.29
- IROQ $16.82
- 52 Week High
- BMEA $13.07
- IROQ $25.76
- Technical
- Relative Strength Index (RSI)
- BMEA 41.35
- IROQ 57.03
- Support Level
- BMEA $1.65
- IROQ $24.00
- Resistance Level
- BMEA $1.85
- IROQ $24.66
- Average True Range (ATR)
- BMEA 0.11
- IROQ 0.09
- MACD
- BMEA -0.01
- IROQ 0.02
- Stochastic Oscillator
- BMEA 5.56
- IROQ 96.15
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About IROQ IF Bancorp Inc.
IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.